## HHS Interim Committee - May 2019

## Edward Redd MD

Chair of Cannabinoid Product Board Logan, UT

# Cannabinoid Product Board – 2018-2019

- Ed Redd, MD (Board Chair)
- Internal Medicine Physician
- Michael J. Crookston, MD, FAPA, FASAM (Board Co-chair)
- Medical Director, Adult Dayspring
- Karen S. Wilcox, Ph.D.
- Professor and Chair, Department of Pharmacology and Toxicology, University of Utah
- Laboratory of Glial/Neuronal Interactions in Epilepsy
- Erik Christensen, M.D.
- Chief Medical Examiner, Utah Department of Health

- Glen R. Hanson, D.D.S., Ph.D.
- Senior Advisor, NIH, College Of Pharmacy
- Director, Utah Addiction Center
- Professor of Pharmacology and Toxicology, University of Utah
- Mark Munger, Pharm.D.
- Professor of Pharmacotherapy
- Adjunct Professor, Internal Medicine, University of Utah
- Perry Renshaw, M.D., Ph.D., M.B.A.
- Medical Director of the VISN 19 Mental Illness Research,
- Education and Clinical Center (MIRECC)
- Salt Lake City Veterans Affairs Medical Center

Additional help from others:

- Rachael Belcher Roseman School of Pharmacy
- Dr Joel Ehrenkranz endocrinologist Intermountain Healthcare
- Dr Perry Fine anesthesia pain management UUMC
- Dr Brian Zehnder family practice
- Dr Lauren Heath Pharm D UUMC
- Dr Katherine Carlson MD, MS psychiatry SUD expertise -UUMC
- Staff from UDOH

- 1690 Section 44. Section 26-61-202 is amended to read:
- 1691 26-61-202. Cannabinoid Product Board -- Duties.
- 1692 (1) The board shall review any available scientific research related to the human use of
- 1693 cannabis, a cannabinoid product, or an expanded cannabinoid product that:
- 1694 (a) was conducted under a study approved by an IRB; or
- 1695 (b) was conducted or approved by the federal government.
- 1696 (2) Based on the research described in Subsection (1), the board shall evaluate the
- 1697 safety and efficacy of cannabis, cannabinoid products, and expanded cannabinoid products,
- 1698 including:
- 1699 (a) medical conditions that respond to cannabis, cannabinoid products, and expanded
- 1700 cannabinoid products;
- 1701 (b) cannabis and cannabinoid dosage amounts and medical dosage forms; [and]
- 1702 (c) interaction of cannabis, cannabinoid products, and expanded cannabinoid products
- 1703 with other treatments[.]; and
- 1704 (d) contraindications, adverse reactions, and potential side effects from use of cannabis,
- 1705 cannabinoid products, and expanded cannabinoid products.

- 1706 (3) Based on the board's evaluation under Subsection (2), the board shall develop
- 1707 guidelines for treatment with cannabis, a cannabinoid product, and an expanded cannabinoid
- 1708 product that include:
- 1709 (a) a list of medical conditions, if any, that the board determines are appropriate for
- 1710 treatment with cannabis, a cannabis product, a cannabinoid product, or an expanded
- 1711 cannabinoid product[.];
- 1712 (b) a list of contraindications, side effects, and adverse reactions that are associated
- 1713 with use of cannabis, cannabinoid products, or expanded cannabinoid products; and
- 1714 (c) a list of potential drug-drug interactions between medications that the United States
- 1715 Food and Drug Administration has approved and cannabis, cannabinoid products, and
- 1716 expanded cannabinoid products.
- 1717 (4) The board shall submit the guidelines described in Subsection (3) to:
- 1718 (a) the director of the Division of Occupational and Professional Licensing; and
- 1719 (b) the Health and Human Services Interim Committee.
- 1720 (5) The board shall report the board's findings before November 1 of each year to the
- 1721 Health and Human Services Interim Committee.

Public Release

Health Effects of Cannabis and Cannabinoids

Current State of Evidence and Recommendations for Research

This report will be available to download as a free pdf: Nationalacademies.org/CannabisHeal thEffects

The National Academies of SCIENCES • ENGINEERING • MEDICINE



# American Herbal Pharmacopoeia®

Cannabis Inflorescence and Leaf

Cannabis L.

STANDARDS OF IDENTITY, ANALYSIS, AND QUALITY CONTROL

Editors Roy Upton RH DAyu American Herbal Pharmacopoeia Scotts Valley, CA Aviva Romm MD CPM American Herbal Pharmacopoeia Lennos, MA Lyle Craker PhD University of Masachusetts Amhent, MA

Technical Advisors and Editors Mahmoud ElSohly PhD University of Mississippi University, MS Ethan Russo MD CW Pharmacenticals plc. Salisbury, UK Michelle Sexton ND BS Americans for Safe Access Washington, DC

**Technical Contributor** Jahan Marcu PhD Temple University School of Medicine Philadelphia, PA

Associate Editor Pavel Asentiev MS American Herbal Pharmacopoeia Scotts Valley, CA

Research Associate Diana Swisher MA American Herbal Pharmacopoeia Scotts Valley, CA






# **INFORMATION FOR HEALTH CARE** PROFESSIONALS

### Cannabis (marihuana, marijuana) and the cannabinoids

Dried or fresh plant and oil administration by ingestion or other means Psychoactive agent

250 pages of detailed information.





Gouvernement du Canada

Goals for Cannabinoid Product Board before November 1, 2019

- Put together the "package insert" for Utah
- Assist UDOH as requested
  - Review of potential on-line CME (continuing medical education)
  - Consistency between CME and "package insert"